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Abstract
Background—Treatment for tuberculosis (TB) is common among individuals receiving stavudine-
containing highly active antiretroviral therapy (HAART), but the effect of TB treatment on stavudine
toxicity has received little attention. We estimated the effect of TB treatment on risk of stavudine
substitution among individuals receiving first-line HAART.
Methods—We evaluated a cohort of 7,066 patients who initiated HAART between April 2004 and
March 2007 in Johannesburg, South Africa. Three exposure categories were considered: ongoing
TB treatment at HAART initiation; concurrent initiation of TB treatment and HAART; incident TB
treatment after HAART initiation. The outcome was single-drug stavudine substitution. Adjusted
hazard ratios (aHRs) were estimated using marginal structural models to control for confounding,
loss to follow-up, and competing risks.
Results—Individuals with ongoing and concurrent TB treatment were at increased risk of stavudine
substitution, irrespective of stavudine dose. For ongoing TB treatment, aHR was 3.18 (95%
confidence interval [CI] 1.82-5.56) in the first two months of HAART, 2.51 (95% CI 1.77-3.54) in
months 3-6, and 1.19 (95% CI 0.94-1.52) thereafter. For concurrent TB treatment, aHR was 6.60
(95% CI 3.03-14.37) in the first two months,1.88 (95% CI 0.87-4.09) in months 3-6, and 1.07 (95%
CI 0.65-1.76) thereafter. There was no effect of incident TB on stavudine substitution risk.
Conclusions—Risk of stavudine substitution was increased among patients receiving TB
treatment, especially soon after HAART initiation. In settings where alternative antiretroviral drugs
are available, initiation of stavudine in patients receiving TB treatment may need to be reconsidered.
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The rapid rollout of highly active antiretroviral therapy (HAART) to individuals living with
human immunodeficiency virus (HIV) has expanded rapidly in the last five years, particularly
in sub-Saharan Africa where access to HAART expanded from 100,000 in 2003 to 1.3 million
people by the end of 2006 [1]. An important challenge faced by HIV/AIDS care programs is
the management of adverse drug reactions in the face of limited human and diagnostic resources
and limited choice of antiretroviral drugs [2-5]. In particular, the inclusion of the nucleoside
reverse transcriptase inhibitor stavudine as a component of standard first-line HAART
throughout sub-Saharan Africa remains controversial. While inexpensive, stavudine causes
significant toxicity and has been implicated as a chief cause of symptomatic hyperlactatemia,
lactic acidosis, lipid disorders, lipodystrophy, and peripheral neuropathy in various populations
of HIV-positive individuals [3,6-10]. In one study from South Africa, over 20% of patients
required substitution of stavudine because of toxicity by 36 months, most often for reasons of
lipodystrophy or peripheral neuropathy [3].
These toxicities may have significant implications for the success of HAART programs as they
cause substantial morbidity [3,10,11], can impact adherence to HAART [2,3], and may lead
to treatment interruptions and virological failure [12]. While the risk factors for
hyperlactatemia, the most clinically severe stavudine toxicity, have been well-characterized,
the risk factors for all-cause stavudine toxicity resulting in substitution remain largely
unexamined [3,13,14]. The impact of concomitant HAART and tuberculosis (TB) treatment
on stavudine substitution remains almost entirely unexplored in sub-Saharan Africa where both
TB and HIV are highly prevalent [15]. This is particularly concerning because isoniazid, a key
component of standard first-line TB treatment [10,16], has been associated with peripheral
neuropathy, one of the most commonly reported stavudine toxicities [3, 10,14,17,18]. We
examined the effect of TB treatment on the incidence of all-cause stavudine substitution in a
large public HIV/AIDS care clinic in Johannesburg, South Africa.
METHODS
Study site, clinic procedures, data collection
This study was conducted in the Themba Lethu Clinical Cohort, a cohort of adults initiating
HAART at one of the largest public clinics providing HAART in South Africa. After initiating
HAART in accordance with the South African National Comprehensive Care, Management
and Treatment Guidelines for HIV and AIDS [16], patients are scheduled for clinical visits at
4 months and every 6 months thereafter, at which demographic, medical, and laboratory data
are collected. All data were entered into a TherapyEdge-HIV™ (TherapyEdge Inc., USA)
database and analyzed in SAS v9.1 (SAS Institute, Cary, NC, USA).
Patients who required TB treatment received a standardized course of directly observed therapy
at primary health care clinics (outside of Themba Lethu Clinic) according to national treatment
guidelines. Date of TB treatment initiation was obtained using TB patient clinic card and patient
self-report to ensure accuracy. The standard first-line of TB treatment in South Africa is two
months of isoniazid, rifampicin, pyramizade, and ethambutol followed by four months of
isoniazid and rifampicin [16]. In South Africa, vitamin B6 (pyridoxine) is commonly
prescribed at time of initiation of TB treatment. In the Themba Lethu Clinic, amitriptyline is
commonly prescribed for individuals experiencing peripheral neuropathy [19].
Study eligibility and definitions
Patients were eligible for analysis if they initiated a stavudine-containing HAART regimen at
Themba Lethu Clinic between 1 April 2004 to 31 March 2007. The exposure of interest was
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TB treatment, defined as patient treatment with isoniazid-containing therapy for pulmonary or
extrapulmonary TB. We hypothesized that the effect of TB treatment on risk of stavudine
substitution might be affected by the relative timing of HAART initiation and TB treatment;
to this end we analyzed three exposure categories. Ongoing TB treatment was defined as TB
treatment started at least 15 days before initiation of HAART, the minimum time advised by
the National Guidelines and the WHO to wait between initiation of TB treatment and HAART
[16,20]. Concurrent TB treatment was defined as initiation of both TB treatment and HAART
within 14 days of each other. Incident TB treatment was defined as initiation of TB treatment
at least 15 days after initiation of HAART, a cutoff chosen to mirror the ongoing TB treatment
category. A schematic diagram for these exposure categories is shown in Figure 1. For all
exposures, the comparison group comprised individuals not receiving TB treatment. The
outcome of all-cause stavudine substitution was defined as the event of substitution of a single
drug (most often zidovudine) for stavudine while the rest of the regimen remained unchanged.
Patients were followed up until they had the event of interest or until censoring at time of
second episode of TB on HAART, death, loss to follow-up, multi-drug substitution, or end of
follow-up (31 March 2007).
Statistical analyses
We performed an intent-to-treat analysis, controlling for confounding and censoring using
inverse probability weighted marginal structural Cox proportional hazards models [21-23].
These methods are similar to Cox proportional hazards models, accounting for confounding
by both baseline and time-varying factors where appropriate; in addition, these models can
adjust analytically for losses to follow-up [24] and competing risks [25]. We controlled for
confounding by gender, ethnicity, employment status, age, history of antiretroviral therapy,
previous history of TB treatment, pregnancy, peripheral neuropathy at HAART initiation,
hemoglobin (adjusted for sex, pregnancy, and altitude), body mass index (BMI), CD4 cell
count, WHO stage, calendar date, whether treatment was initiated after October 2006 (when
all consultation fees were eliminated), and stavudine dose (milligrams per kilogram).
In these analyses, patients became exposed at the earliest time they were receiving both
HAART and TB treatment. However, we expected the effect of TB treatment to change with
total time on both TB treatment and HAART. Time-interaction terms were included in all
analyses to allow models to estimate these different effects by months of co-treatment: 0-2
months, 3-6 months, and 7+ months. Last, we performed several sensitivity analyses (described
below). Further details of the statistical analysis are given in the Appendix.
Ethics approval
This study was approved by the human subjects review boards of both the University of the
Witwatersrand and the University of North Carolina at Chapel Hill.
RESULTS
We analyzed 7,066 individuals who initiated stavudine-containing HAART, among whom
there were a total of 1,845 cases of active TB. Of these cases, 1,272 were cases of ongoing TB
treatment (716 for more than two months and 556 for less), 224 were cases of concurrent
initiation of treatment, and 349 were cases of incident TB treatment (132 early, between 15
and 60 days of HAART initiation; and 217 more than 60 days after HAART initiation). Patients
with either ongoing or concurrent TB treatment were less likely at time of HAART initiation
to have a history of TB, and were more likely to be male and have advanced disease (lower
CD4 counts, low BMI, low hemoglobin, more WHO stage IV disease) compared to those who
not receiving TB treatment, and were more likely to receive a reduced (30mg) dose of stavudine
(Table 1). Patients who later developed TB likewise had lower baseline BMI, CD4 count, and
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hemoglobin than those not receiving TB treatment at baseline, and were similarly more likely
to receive a reduced dose of stavudine.
Among the 7,066 individuals, 260 individuals (3.7%) died, 1,252 (17.7%) became lost to
follow-up, and 1,219 (17.3%) experienced stavudine substitutions. Of these, 842 were single-
stavudine substitutions, 203 were multi-drug substitutions, and 172 were switches to second-
line HAART (zidovudine/didanosine/lopinavir-ritanovir). The crude rate of single-stavudine
substitution in the entire cohort was 12.4 (95% CI 11.6-13.3) per 100 person-years with a
median time to single-stavudine substitution of 347 (IQR 175-535) days. As expected, absolute
rate of stavudine substitution increased with time since HAART initiation, from months 0-6
(7.9, 95% CI 6.9-9.1 substitutions per 100 person-years), to months 6-12 (12.3, 95% CI
10.8-14.0), and to the rest of follow-up (18.1, 95% CI 16.4-20.0). This increasing rate is evident
in Figure 2, which shows Kaplan-Meier curves for single-stavudine substitutions stratified by
baseline TB treatment exposure category. These curves show an increased risk of stavudine
substitution in the first months of concomitant TB and HAART compared to those not receiving
TB treatment, and no increased risk due to TB treatment after 6 months (vertical dashed line);
at the same time, these curves show that the absolute rate of stavudine substitution increases
at six months and again at one year.
Hazard ratios adjusted for confounding, loss to follow-up, death, and the competing risk of
multi-drug substitution are shown in Table 2. Crude results were similar to adjusted results
(data not shown). Among people with ongoing TB treatment at time of HAART initiation,
adjusted hazard ratio (aHR) for stavudine substitution was 3.18 (95% CI 1.82-5.56) in the first
two months of HAART, 2.51 (95% CI 1.77-3.54) for months 3-6, and 1.19 (95% CI 0.94-1.52)
thereafter. Among people with concurrent initiation of treatment for TB and HAART, aHR
was 6.60 (95% CI 3.03-14.37) in the first two months of HAART, 1.88 (95% CI 0.87-4.09)
for months 3-6, and 1.07 (95% CI 0.65-1.76) thereafter. Among people with incident TB
treatment after HAART initiation, the aHR was not different from the referent group and
imprecise in all three time periods (Table 2). Early incident TB treatment tended to be
associated with increased risk of stavudine substitution in the first two months of co-treatment
with an aHR of 2.74 (95% CI 0.84-8.94).
Almost half (362 or 43%) of the 842 single-stavudine substitutions were attributed to clinically-
diagnosed peripheral neuropathy, 24% to lipodystrophy (n=205), 20% to lactic acidosis or
symptomatic hyperlactatemia (n=168), 2% to a combination of these toxicities (n=21); the
remainder (11%) had no reason recorded. Patients who switched due to peripheral neuropathy
were more likely to have TB at HAART initiation or during follow-up (RR=1.53, 95% CI
1.33-1.75), whereas those who switched for lactic acidosis or lipodystrophy were less likely
to have TB (RR=0.58, 95% CI 0.48-0.71).
Sensitivity analysis
Sensitivity analyses indicated that main results were not sensitive to absolute stavudine dose
(30 or 40 milligrams), inclusion of multi-drug substitutions, or total TB treatment lasting nine
months (rather than six). We found that restricting analysis to those without recorded history
of TB resulted in slightly elevated hazard ratios for both ongoing and concurrent analyses in
months 0-2 (ongoing: aHR=3.56 versus baseline 3.18; for concurrent, 7.57 versus 6.60). This
suggested that lingering peripheral neuropathy from previous drug exposures might have
biased the results toward the null.
DISCUSSION
Concomitant administration of TB treatment and HAART is common in sub-Saharan Africa,
especially at time of initiation of HAART. Our results show that concurrent initiation of TB
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treatment and stavudine-based HAART within a 2 week window puts patients at a nearly seven-
fold increased risk of substitution for stavudine in the first two months of HAART (aHR=6.60,
95% CI 3.03-14.37), and some increased risk until six months after HAART initiation.
Likewise, initiation of stavudine in patients whose TB treatment was ongoing for more than 2
weeks at time of HAART initiation was associated with a two- to three-fold increased risk of
stavudine substitution over the first six months of HAART. The presence of an effect of both
ongoing and concurrent TB treatment within six months of HAART initiation are evident in
crude results shown in Figure 2, where survival curves diverge sharply in the first six months,
but are similar (essentially parallel) thereafter. In general, there was little to no effect of incident
TB treatment on risk of stavudine substitution, although there was a suggestion that early
incident TB might raise the risk of stavudine substitution. Risks remained elevated even among
patients who received a twice daily 30mg dose of stavudine, per current WHO
recommendations, and were not confounded by stavudine dose (milligrams per kilogram).
These results, based on a large sample size and robust analytic methods, confirm and extend
the results of two small studies from England, in which higher than expected rates of adverse
events with stavudine and TB treatment were observed [27,28].
Almost half (43%) of single-stavudine substitutions could be attributed to peripheral
neuropathy; individuals receiving TB treatment were more likely than others to switch for
reason of peripheral neuropathy (RR=1.53). This is consistent with the hypothesis that
peripheral neuropathy is a key symptomatic pathway for the interaction of TB drugs and
HAART. Peripheral neuropathy is caused by both isoniazid [10,18] and stavudine [3,14,17,
18,27,28] through different mechanisms; use of both drugs may lead to an additive or
cumulative effect, increasing severity of symptoms.
Indeed, these results may understate the true impact of stavudine and TB treatment, for three
reasons: first, because the great majority of TB patients in South Africa are prescribed vitamin
B6 (pyridoxine) at time of initiation of TB treatment for the prevention of peripheral
neuropathy, and in addition, amitriptyline is frequently prescribed to manage incident
peripheral neuropathy. It is possible that the effect of TB on the risk of stavudine substitution
would be even higher in settings where these drugs were not routinely used; conversely rates
of peripheral neuropathy may be further reduced with additional micronutrient
supplementation [29].
Second, restricting the reference group to individuals without a history of TB yielded higher
effect estimates for analysis of concurrent and ongoing TB treatment. This suggests that main
analyses could have underestimated the true impact of TB treatment on risk of stavudine
substitution, perhaps due to residual peripheral neuropathy among those with a recent history
of TB treatment.
Third, while focusing on stavudine substitution as the outcome ensures that we capture the
most severe toxicities, we did not examine the impact of TB treatment on risk of mild stavudine
toxicity. It is likely that treatment for TB resulted in additional low level peripheral neuropathy,
which may remain undiagnosed, unreported, or resolves without stavudine substitution. Thus,
the impact of TB treatment on risk of stavudine toxicities may be higher than the effect of TB
treatment on risk of stavudine substitution.
It was surprising that incident TB treatment, and in particular late incident TB treatment, was
not associated with an increase in stavudine substitution; this may be the result of depletion of
susceptible patients. An alternate hypothesis is that the effect of TB treatment on risk of
stavudine-related toxicity is mediated by HIV viral load. Control of HIV replication would
then reduce the effect of TB treatment on risk stavudine substitution.
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TB treatment did not increase risk of stavudine substitution after six months (the duration of
a typical course of TB treatment). However, the bulk of stavudine substitution occurs after six
months; it is important to note that while the relative rate of stavudine substitution attributable
to TB treatment was not significant after six months in any exposure group, the absolute rate
of stavudine substitution increased substantially after both six and twelve months of HAART.
A related point is that, because the absolute risk of stavudine substitution is relatively low in
the six months following initiation of stavudine, even a large hazard ratio may translate into a
relatively small absolute risk difference. Only 219 stavudine substitutions took place during
the first six months following initiation of HAART among patients at risk for that period. The
absolute risk in those with any TB treatment at baseline (ongoing or concurrent) was 5.7%,
and in those without was 2.4% (risk difference 3.3%, 95% CI 2.0-4.5%), corresponding to one
stavudine substitution for every 18 patients with TB treatment and one for every 42 patients
without any TB treatment. Because of the large number of individuals who initiate HAART
while on TB treatment (>20%) in this population, we believe these results remain of
considerable public health relevance.
There were several limitations of this study. First, this observational study was conducted in
a busy clinic setting using routinely collected data; results are therefore necessarily less
definitive than they would be in a randomized trial. In particular, while we strove to control
adequately for confounding, uncontrolled confounding may still be present, including exposure
to alcohol and other drugs associated with peripheral neuropathy. Similarly, while we corrected
for bias due to competing risks including death, LTFU, and multi-drug substitution, complete
control of such bias depends on the difficult-to-verify assumption that competing risks can be
completely explained by observed variables [24,25]. Last, if patients receiving stavudine and
isoniazid were evaluated more thoroughly for peripheral neuropathy than comparable patients,
this might lead to detection or diagnostic bias that might result in an overestimation of the
effect. Future studies of this topic should use blinded evaluation of peripheral neuropathy to
eliminate this potential bias.
In conclusion, results show that in this patient population, concurrent initiation of TB treatment
and HAART, as well as initiation of HAART while receiving ongoing TB treatment, is an
important risk factor for stavudine substitution, irrespective of stavudine dose. These results
suggest that screening for peripheral neuropathy is important in patients receiving d4T and TB
treatment, especially those initiating both treatments within a short period. Moreover, in
settings where alternative antiretroviral drugs are available, we may wish to reconsider the use
of stavudine in first-line HAART among patients with ongoing or concurrent initiation of TB
treatment.
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Appendix: details of statistical models
All adjusted hazard ratios were estimated using baseline-stratified stabilized inverse
probability weighted marginal structural models, implemented as weighted pooled log-
binomial models. This model was baseline-stratified (a non-standard term in the literature) in
that we controlled for confounding by baseline factors by including these variables in the final
structural (i.e., regression) model; thus, resulting effect estimates are not fully marginal. The
approach is common in marginal structural models (e.g. [22]), and is expected to improve
variance of the estimate as compared to a pure reweighting approach for these factors. In the
analysis of incident TB treatment, we also controlled for confounding by time-varying factors
using inverse probability of treatment weights, and used baseline factors to stabilize these
weights.
Inverse probability weights were also used to control for non-confounding bias, including
censoring (lost to follow-up, death, or switches to second-line HAART) and the competing
risk of multi-drug substitution including stavudine. The inclusion of competing risk weights
in overall inverse probability weights has only been described once previously in the literature
[25], but the intuition behind such an application of inverse probability weights is
straightforward, simply assuming multiple censoring categories.
Covariates considered for inclusion in all models included gender, ethnicity, employment
status, age, history of antiretroviral therapy, history of TB; baseline measures of pregnancy,
peripheral neuropathy, hemoglobin (adjusted for sex, pregnancy, and altitude), body mass
index (BMI), CD4 cell count, and WHO stage (IV or other), calendar date, whether clinical
care was free at time of treatment initiation (before/after October 2006), and stavudine dose
(milligrams per kilogram). Time varying models (of the exposure of incident TB treatment,
censoring, or competing risks) also considered time-updated measures of hemoglobin, CD4
count, BMI, and virologic success (measured only after month 6), and month of follow-up as
both a continuous and categorical variable.
Possible confounding variables were removed from consideration using a backwards
elimination approach with a combined criterion of log-scale change-in-estimate of 0.10 and a
chi-square p-value >0.10. The final variables used to control confounding were (for both main
exposures): gender, age, history of antiretroviral therapy, pregnancy, peripheral neuropathy at
baseline, BMI, year of HAART initiation, and whether clinical care was free or not, and
stavudine dose (milligrams per kilogram). We did not implement a selection process for models
for stabilized censoring or competing risk weights; in both cases, all baseline variables and the
exposure were included in stabilizing portions of weights (numerators), while all baseline and
time-updated covariates as well as the exposure were included in weight models
(denominators) [24]. All weights were estimated using logistic regression.
The positivity assumption requires that there be no combination of observed confounders
(covariates) that predicts exposure (treated for TB, or not treated for TB) in a deterministic
way [30]. We evaluated the positivity assumption by visually examining histograms of
multivariate predicted probability of exposure by observed exposure status (a process
equivalent to the comparison of propensity score distributions). Because there was substantial
overlap in these curves, we judged that the positivity assumption was approximately met in
these data for the exposures of interest.
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Schematic diagram of TB treatment exposure categories in relation to time of HAART
initiation (ongoing, concurrent, incident).
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Kaplan-Meier analysis of time to stavudine substitution by TB treatment status at time of
HAART initiation, among 7,066 individuals initiating HAART in Johannesburg, South Africa.
Westreich et al. Page 11

























Westreich et al. Page 12
Table 1
Baseline characteristics of 7066 individuals at time of HAART initiation in Johannesburg, South Africa, by













Pulmonary TB n/a 964 (75.8) 164 (73.2) 275 (79.9)
History of TB 792 (15.2) 64 (5.0) 13 (5.8) 62 (18.0) *
Stavudine dose
 40 mg 2879 (55.1) 515 (40.5) 89 (39.7) 150 (43.6)
 30 mg 2184 (41.8) 743 (58.4) 130 (58.0) 185 (53.8)
 Missing 163 (3.1) 14 (1.1) 5 (2.2) 9 (2.6)
Female gender 3634 (69.5) 749 (58.9) 128 (57.1) 212 (61.6)
Age > 40 1536 (29.4) 347 (27.3) * 68 (30.4) * 112 (32.6) *
Employed 1988 (38.0) 396 (31.1) 79 (35.3) * 112 (32.6) *
Body mass index (kg/m2)
 < 18.5 815 (15.6) 412 (32.4) 68 (30.4) 78 (22.7)
 18.5 - 24.9 2872 (55.0) 707 (55.6) 122 (54.5) 201 (58.4)
 25.0 - 29.9 1049 (20.1) 124 (9.8) 25 (11.2) 50 (14.5)
 ≥ 30.0 490 (9.4) 29 (2.3) 9 (4.0) 15 (4.4)
















 < 50 1498 (28.7) 525 (41.3) 112 (50.0) 139 (40.4)
 50 - 99 954 (18.3) 303 (23.8) 40 (17.9) 72 (20.9)
 100 - 199 1729 (33.1) 306 (24.1) 49 (21.9) 89 (25.9)
 200 - 349 489 (9.4) 46 (3.6) 10 (4.5) 14 (4.1)
 ≥ 350 112 (2.1) 13 (1.0) 3 (1.3) 3 (0.9)
 Missing 444 (8.5) 79 (6.2) 10 (4.5) 27 (7.9)
WHO stage IV 412 (7.9) 228 (17.9) 49 (21.9) 33 (9.6) *
Peripheral neuropathy 138 (2.6) 81 (6.4) 11 (4.9) * 11 (3.2) *
Incident TB column comprises only subjects who had no TB at baseline. P-values are 2-sided by chi-square test compared to “No TB treatment”; means
compared by t-test, medians by Wilcoxon rank sum test.
After adjustment for altitude, lower limit of normal hemoglobin is 12.35/11.35/10.35 g/dl for men, women, and pregnant women respectively.
All comparisons were significant at p < 0.01 level except for those indicated with *.
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Table 2
Adjusted hazard ratios and 95% confidence intervals for the effect of TB treatment on stavudine substitution by
timing of TB treatment initiation relative to HAART initiation and duration of co-treatment, among 7,066
individuals initiating HAART in Johannesburg, South Africa.
TB treatment n Months of TB/HAART treatment0-2 3-6 7+
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